Drug Trial Radar · NCT05691465
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Dec 27, 2023
Primary completion
Jun 1, 2027
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refers to cells that have traits of both hormone-producing endocrine cells and nerve cells. These cells release hormones into the blood in response to a signal from the nervous system. Hormones are biological substances that circulate through the bloodstream to control the activity of other organs or cells in the body. Lutetium Lu 177-dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Treatment with Lutetium Lu 177 dotatate may shrink the tumor in a way that can be measured in patients with metastatic prostate cancer with neuroendocrine differentiation.
Conditions
- Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation
- Metastatic Prostate Neuroendocrine Carcinoma
- Metastatic Prostate Small Cell Neuroendocrine Carcinoma
- Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo collection of blood
Computed TomographyProcedure
Undergo CT scan
Gallium Ga 68-DOTATATERadiation
Given IV
Lutetium Lu 177 DotatateDrug
Given IV
Positron Emission TomographyProcedure
Undergo PET
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: At 6 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California · Suspended
Los Angeles General Medical Center
Los Angeles, California · Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Active not recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Kentucky/Markey Cancer Center
Lexington, Kentucky · Recruiting
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland · Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas · Recruiting
UT MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin · Recruiting
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.